<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03828942</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-19-01</org_study_id>
    <nct_id>NCT03828942</nct_id>
  </id_info>
  <brief_title>Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)</brief_title>
  <acronym>HeMATOX</acronym>
  <official_title>Monitoring the HeMAtological TOXicity of Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several drugs and chemotherapies seem to have an impact on the hematological system. This
      study investigates reports of hematological toxicities, including the International
      classification of disease ICD-10 for treatments in the World Health Organization (WHO) global
      Individual Case Safety Report (ICSR) database (VigiBase).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several drugs and chemotherapies seem to have an impact on the hematological system and are
      responsible of a wide range of hematological side effects. Those are poorly described, due to
      the modification of the pharmacopeia, and the recent recognition of several of these adverse
      events. This study investigates the main characteristics of patients affected by rare
      hematological side effects imputed to drugs. A causality assessment according to the WHO-UMC
      (World Health Organization - Uppsala Monitoring Center) is systematically applied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Hematological toxicities of drugs Identification and report of cases of hematological toxicities associated with drugs.</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Causality assessment of reported hematological toxicities events according to the WHO system</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the type of hematological toxicity depending on the category of drug</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the other immune related adverse events concomitant to the hematological toxicity induced by drugs</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the duration of treatment when the toxicity happens (role of cumulative dose)</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the drug-drug interactions associated with adverse events</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pathologies (cancer) for which the incriminated drugs have been prescribed</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having hematological toxicity adverse event</measure>
    <time_frame>to 01/02/2019</time_frame>
    <description>Case reported in the World Health Organization (WHO) database of individual safety case reports</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hematological Abnormality</condition>
  <condition>Hematotoxicity</condition>
  <arm_group>
    <arm_group_label>Hematological toxicity induced by drugs and chemotherapies</arm_group_label>
    <description>Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug inducing hematological toxicity</intervention_name>
    <description>Drugs susceptible to induce hematological toxicities</description>
    <arm_group_label>Hematological toxicity induced by drugs and chemotherapies</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with a drug that could be reported in the WHO's pharmacovigilance database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case reported in the WHO's pharmacovigilance database till 01/02/2019

        Exclusion Criteria:

          -  Chronology not compatible between the drug and the toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe-Elie Salem, Md, PhD</last_name>
      <phone>(0)1 42 17 85 33</phone>
      <phone_ext>+33</phone_ext>
      <email>joe-elie.salem@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhumatology department, CHU Strasbourg, Hautepierre hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Arnaud, MD, PhD</last_name>
      <phone>(0)3 88 12 84 74</phone>
      <phone_ext>+33</phone_ext>
      <email>laurent.arnaud@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>Assistant director, clinical investigation center Paris Est</investigator_title>
  </responsible_party>
  <keyword>advrese event</keyword>
  <keyword>hematotoxicity</keyword>
  <keyword>drugs</keyword>
  <keyword>chemotherapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

